Cohance Lifesciences balance sheet

As of Mar 2026

Total assets: ₹5,730cr+89.0% on Mar 2025
Shareholders' equity: ₹4,034cr+119.2% on Mar 2025
Total debt: ₹170cr+117.2% on Mar 2025
Cash and investments: ₹315cr+13.8% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1,990	995	567	584
	173	255	179	165
	1,284	655	0.0	0.0
	95.0	63.1	102	79.1
	4.5	0.8	0.1	0.0
	262	145	131	117
	1.3	4.6	0.0	0.0
	32.4	18.6	9.4	5.9
	296	168	140	123
	2.6	0.6	—	0.0
	56.6	5.5	2.2	3.3
	3,902	2,143	991	955
	562	167	231	313
	266	192	774	419
	681	284	134	111
	49.1	85.4	47.2	64.8
	10.5	3.3	3.3	3.2
	8.0	0.4	0.8	0.2
	1.8	10.0	0.4	0.3
	1,017	575	959	598
	217	111	62.7	99.9
	1,796	853	1,263	1,011
	31.7	35.3	0.0	0.0
	5,730	3,032	2,254	1,966
Equity
	38.3	25.5	25.5	25.5
	3,873	1,671	2,025	1,710
	3,911	1,697	2,051	1,735
	123	144	—	—
	4,034	1,841	2,051	1,735
Liabilities
	50.5	6.2	0.0	4.6
	901	728	21.2	0.7
	952	735	21.2	5.3
	0.4	0.3	10.5	8.3
	97.9	91.0	64.8	58.2
	1,050	826	96.5	71.8
	119	71.9	38.6	64.6
	285	80.2	42.4	65.2
	119	187	14.0	21.8
	523	339	95.0	152
	47.3	17.9	4.7	3.9
	16.4	1.1	0.0	0.3
	59.4	7.1	7.2	3.0
	646	365	107	159
	1,696	1,191	203	231
	5,730	3,032	2,254	1,966
Assets — additional as-filed lines
	0.1	0.0	10.0	0.0
Trade payables — MSME split
	45.3	11.7	—	—
	239	68.5	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

COHANCE₹481.35

Cohance Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB SYNGENE ASTERDM LALPATHLAB NATCOPHARM WOCKPHARMA NEULANDLAB NHMcap ₹18,416 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	584.2	567.2	995.2	1,990.1	1,990.1
+ Capital Work-in-Progress	165.1	179.0	254.8	173.2	173.2
+ Goodwill	0.0	0.0	655.1	1,283.7	1,283.7
+ Other Intangibles	79.1	102.4	63.1	95.0	95.0
+ Intangibles under Development	0.0	0.1	0.8	4.5	4.5
+ Non-current Investments	117.1	130.6	145.0	262.2	262.2
+ Long-term Loans	0.0	0.0	4.6	1.3	1.3
+ Other Non-current Financial Assets	5.9	9.4	18.6	32.4	32.4
Non-current Financial Assets	123.0	140.0	168.1	296.0	296.0
+ Deferred Tax Assets	0.0	—	0.6	2.6	2.6
+ Other Non-current Assets	3.3	2.2	5.5	56.6	56.6
Total Non-current Assets	954.7	990.9	2,143.2	3,901.7	3,901.7
Current Assets
+ Inventories	312.8	231.2	166.6	562.2	562.2
+ Current Investments	418.9	773.9	191.7	266.3	266.3
+ Trade Receivables	110.9	133.7	284.4	681.0	681.0
+ Cash & Cash Equivalents	64.8	47.2	85.4	49.1	49.1
+ Other Bank Balances	3.2	3.3	3.3	10.5	10.5
+ Short-term Loans	0.2	0.8	0.4	8.0	8.0
+ Other Current Financial Assets	0.3	0.4	10.0	1.8	1.8
Current Financial Assets	598.4	959.3	575.2	1,016.8	1,016.8
+ Other Current Assets	99.9	62.7	111.5	217.2	217.2
Total Current Assets	1,011.0	1,263.2	853.3	1,796.3	1,796.3
+ Assets Held for Sale	0.0	0.0	35.3	31.7	31.7
Total Assets	1,965.7	2,254.1	3,031.8	5,729.6	5,729.6
Equity
+ Equity Share Capital	25.5	25.5	25.5	38.3	38.3
+ Other Equity / Reserves	1,709.7	2,025.2	1,671.1	3,873.0	3,873.0
Equity — Owners of Parent	1,735.2	2,050.7	1,696.6	3,911.3	3,911.3
+ Minority Interest	—	—	144.1	122.5	122.5
Total Equity	1,735.2	2,050.7	1,840.6	4,033.8	4,033.8
Liabilities
+ Borrowings — Non-current	4.6	0.0	6.2	50.5	50.5
+ Other Non-current Financial Liab	0.7	21.2	728.4	901.1	901.1
Non-current Financial Liabilities	5.3	21.2	734.7	951.6	951.6
+ Provisions — Non-current	8.3	10.5	0.3	0.4	0.4
+ Deferred Tax Liabilities	58.2	64.8	91.0	97.9	97.9
Non-current Liabilities	71.8	96.5	825.9	1,049.9	1,049.9
+ Borrowings — Current	64.6	38.6	71.9	119.2	119.2
+ Trade Payables	65.2	42.4	80.2	284.6	284.6
+ Other Current Financial Liab	21.8	14.0	187.1	119.0	119.0
Current Financial Liabilities	151.6	95.0	339.2	522.8	522.8
+ Provisions — Current	3.9	4.7	17.9	47.3	47.3
+ Current Tax Liabilities	0.3	0.0	1.1	16.4	16.4
+ Other Current Liabilities	3.0	7.2	7.1	59.4	59.4
Current Liabilities	158.8	106.9	365.2	645.9	645.9
Total Liabilities	230.6	203.4	1,191.1	1,695.8	1,695.8
Total Equity & Liabilities	1,965.7	2,254.1	3,031.8	5,729.6	5,729.6
Assets — additional as-filed lines
+ Current Tax Assets	0.0	10.0	0.0	0.1	0.1
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	—	11.7	45.3	45.3
+ Dues to Other Creditors — Current	—	—	68.5	239.3	239.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.